Compare ARLP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | TVTX |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 1999 | N/A |
| Metric | ARLP | TVTX |
|---|---|---|
| Price | $24.25 | $35.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $29.50 | ★ $37.21 |
| AVG Volume (30 Days) | 270.1K | ★ 1.6M |
| Earning Date | 10-27-2025 | 10-30-2025 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $2,249,390,000.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.36 |
| Revenue Next Year | $3.41 | $37.33 |
| P/E Ratio | $12.81 | ★ N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $22.20 | $12.91 |
| 52 Week High | $30.56 | $37.50 |
| Indicator | ARLP | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 56.76 |
| Support Level | $23.50 | $33.45 |
| Resistance Level | $24.60 | $35.64 |
| Average True Range (ATR) | 0.60 | 1.51 |
| MACD | 0.01 | -0.40 |
| Stochastic Oscillator | 55.22 | 39.01 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties has included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.